Navigation Links
Gene may be good target for tough-to-kill prostate cancer cells

WEST LAFAYETTE, Ind. - Purdue University scientists believe they have found an effective target for killing late-stage, metastatic prostate cancer cells.

Xiaoqi Liu, an assistant professor of biochemistry and member of Purdue's Center for Cancer Research, and graduate student Shawn Liu are focusing on the function of a gene called Polo-like kinase (Plk1), a critical regulator of the cell cycle. Plk1 is also an oncogene, which tends to mutate and can cause cancer.

The researchers found that later-stage prostate cancer cells are missing Pten, a tumor-suppressor gene. The loss of Pten causes problems during cell division. Instead of the parent cell giving equal copies of DNA to two daughter cells, those new cells receive disproportionate amounts, causing mutations.

"This turns out to be a major driving factor in future cancer," said Xiaoqi Liu, whose findings were published in the Journal of Biological Chemistry. "Without Pten, there is huge potential to become a cancer cell."

When Pten is diminished, the cells become stressed. To compensate, they increase production of Plk1, which causes rapid cell division.

"That's usually a hallmark of cancer formation," Xiaoqi Liu said.

This particular type of later-stage prostate cancer is troublesome because the cells do not respond to drugs aimed at stopping cell division and metastatic cancers spread to other areas. When Pten is missing, Xiaoqi Liu said, those drugs actually increase the production of more Plk1.

To test the theory that Plk1 is a key to cancer formation, the researchers tested a Plk1 inhibitor called BI 2356 on both human cancer cells and mice. In both tests, some cancer cells had Pten present while others had lost it.

In both cases, the cells without Pten responded to the drug.

"In later stages of prostate cancer, cells have lost Pten," Xiaoqi Liu said. "This means the Plk1 inhibitor can be a good drug for treatment of those tumors."

Xiaoqi Liu said tests also showed that BI 2536 could also be effective at low dosages, meaning side effects might be less severe.

Next, the researchers will try to replicate the findings in another mouse model.


Contact: Brian Wallheimer
Purdue University

Related medicine news :

1. Could targeting a virus treat a common pediatric brain tumor?
2. New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients
3. Researchers identify potential molecular target to prevent growth of cancer cells
4. Targeting cholesterol may help slow glioblastoma
5. Targeting cholesterol to fight deadly brain cancers
6. $1.1 million grant targets disparities among medical researchers
7. Study points to strategy for overcoming resistance to targeted cancer drug
8. Cell receptor could allow measles virus to target tumors
9. Penn study on silencing of tumor suppressor gene suggests new target for lymphoma
10. USC scientist develops virus that targets HIV
11. Targeting innate immunity in malaria
Post Your Comments:
Related Image:
Gene may be good target for tough-to-kill prostate cancer cells
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: